Vera Therapeutics

Yahoo Finance • 21 days ago

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-q... Full story

Yahoo Finance • last month

Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunol... Full story

Yahoo Finance • 2 months ago

Wolfe Research downgrades Vera Therapeutics stock rating on limited catalysts

Investing.com - Wolfe Research downgraded Vera Therapeutics (NASDAQ:VERA) from Outperform to Peerperform on Monday. According to InvestingPro data, the company maintains a FAIR financial health score, with analysts setting price targets... Full story

Yahoo Finance • 3 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase... Full story

Yahoo Finance • 3 months ago

Millions in Insider Buying Point to These 2 Stocks — Here’s What It Could Signal

There’s a current of optimism in the air as Wall Street’s stock markets climb back to record levels, with the S&P 500 hitting an all-time high yesterday. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premium at 50% off!... Full story

Yahoo Finance • 3 months ago

Thursday 6/26 Insider Buying Report: VERA, GMRE

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is th... Full story

Yahoo Finance • 3 months ago

Vera Therapeutics director Enright buys shares worth $5.2m

Director Patrick G. Enright of Vera Therapeutics , Inc. (NASDAQ:VERA) recently purchased shares of Class A Common Stock. On June 23 and 24, 2025, Enright acquired a total of 250,690 shares at prices ranging from $20.8683 to $22.3517, resu... Full story

Yahoo Finance • 4 months ago

Vera plunges as Otsuka outperforms with IgA nephropathy therapy

[USA Recession and Crashing Economy Concept] mphillips007 Vera Therapeutics (NASDAQ:VERA [https://seekingalpha.com/symbol/VERA]) fell ~32% in the premarket on Friday after late-stage trial data indicated that the company’s lead asset, ata... Full story

Yahoo Finance • 4 months ago

Vera Therapeutics announces refinancing of Oxford debt facility with access to up to $500M in term loans

* Vera Therapeutics (NASDAQ:VERA [https://seekingalpha.com/symbol/VERA]) Tuesday announced [https://seekingalpha.com/pr/20123922-vera-therapeutics-announces-refinancing-of-existing-oxford-debt-facility-providing-up-to-500] that it has en... Full story

Yahoo Finance • 4 months ago

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

Vera Therapeutics BRISBANE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with seri... Full story

Yahoo Finance • 4 months ago

Vera rises after success in late-stage trial for IgA nephropathy treatment

[Human Kidneys - Medical Illustration] peterschreiber.media/iStock via Getty Images Shares of Vera Therapeutics (NASDAQ:VERA [https://seekingalpha.com/symbol/VERA]) rose after the company said on Monday it achieved its main goal in a late... Full story

Yahoo Finance • 4 months ago

Why Vera Therapeutics Is Rising In Pre-market?

(RTTNews) - Vera Therapeutics (VERA) announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy in adults. Participants treated with atacicept achieved a 46% reduc... Full story

Yahoo Finance • 4 months ago

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)Other... Full story

Yahoo Finance • 7 months ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; BLA submission to the U.S. FDA for accelerated approval planned in 2H 2025Expanded atacicept clinical de... Full story

Yahoo Finance • last year

Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024?

We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, we will look at where Vera Therapeutics Inc. (NASDAQ:VERA) ranks among the best-performing small-cap stocks in 2024. The Case for Small Caps... Full story

Yahoo Finance • 2 years ago

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Phase 2b open-label extension eGFR and proteinuria data expected in the first quarter of 2024; actively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept in IgAN Announced analysis of Phase 2b ORIGIN study showing reso... Full story

Yahoo Finance • 2 years ago

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

Analysis of week 36 data from Phase 2b ORIGIN study shows atacicept 150 mg substantially reduces serum Gd-IgA1 and resolves hematuria in the majority of patients. Additional poster presentations provide further safety analysis of Phase 2b... Full story

Yahoo Finance • 2 years ago

Vera Therapeutics Scheduled to Present at November Investor Conferences

BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunol... Full story

Yahoo Finance • 2 years ago

Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating ataciceptin IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting atacicept’s potent... Full story

Yahoo Finance • 2 years ago

Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk p... Full story